Baptist Ambulance offering a free 8-week EMT course in Memphis localmemphis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localmemphis.com Daily Mail and Mail on Sunday newspapers.
Infoblox 3.0 delivers secure, cloud-first network experiences by unifying NIOS and BloxOne platforms.
Santa Clara, Calif.,
June 8, 2021
Infoblox Inc., the leader in core network and security services, today embarks on Infoblox 3.0, focused on delivering a secure cloud-first network experience. The company is uniting NIOS, the industry leading on-premises DDI solution, with its cloud-native BloxOne Threat Defense and BloxOne DDI platforms to help customers bridge core networking and security into cloud environments that underpin the needs of the modern enterprise.
Infoblox 3.0 harnesses the industry s leading DDI and DNS security solutions to enable on-premises, virtual, cloud and hybrid deployments tailored to customers network modernization needs. Enabling these deployments ensure customers can grow their networks in a way that is:
Editor’s Note: The Human Impact is an ongoing series about marginalized people in our communities and the disproportionate impact of COVID-19 upon them.
The Leukemia & Lymphoma Society Launches Impact Research Grants To Help Underserved Patients Access Clinical Trials
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials
News provided by
Share this article
RYE BROOK, N.Y., May 13, 2021 /PRNewswire/
The Leukemia & Lymphoma Society (LLS) announced today the launch of the IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants to increase enrollment of individuals from underrepresented communities in clinical trials. Clinical trials are vital to improving cancer treatment, giving newly diagnosed patients access to state-of-the-art therapies, and providing a lifeline when other treatments have failed. Yet, clinical trials overwhelmingly fail to represent certain patient populations such as ethnic and racial minorities and people in rural co
View Comments
This is a reporter’s notebook column by breaking news reporter Micaela Watts, who has spent the last year covering the COVID-19 pandemic in Memphis from her home office, until a phone call sent her into one of the area COVID-19 wards.
The nurse began preparing me as we wound our way through the labyrinth of the still-new Shorb Tower at Methodist University hospital.
I had been told one family member could visit a day, for one hour a day while she was in palliative care. But her oxygen was nosediving, quickly. The staff had alerted my father, who called me and said, “You should be the one to go.”